# Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria

> **NCT02633046** · PHASE4 · COMPLETED · sponsor: **Mallinckrodt ARD LLC** · enrollment: 63 (actual)

## Conditions studied

- Idiopathic Focal Segmental Glomerulosclerosis

## Interventions

- **DRUG:** Acthar Gel

## Key facts

- **NCT ID:** NCT02633046
- **Lead sponsor:** Mallinckrodt ARD LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-10
- **Primary completion:** 2020-08-27
- **Final completion:** 2020-08-27
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2021-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02633046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02633046, "Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02633046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*